$CSTM

Ormerod John sold $280K of CSTM

Ormerod John sold 8,000 shares of CONSTELLIUM SE (CSTM) at $35.01 ($0.28M total) on 2026-06-04.

Original reporting
SEC EDGAR · Ormerod John
Published Jun 8, 2026, 1:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 1:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CSTM
Neutral
medium confidence
Mentioned
$CSTM
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTMNeutralLow
01

Why it matters

Provides a fresh, dated datapoint on insider behavior for CSTM, but does not include any new company-specific fundamental catalyst.

02

Market read

Useful for monitoring insider activity, but not a standalone fundamental catalyst.

03

What to watch

No 10b5-1 plan is cited; traders may want to check whether this director has a history of clustered sales or whether other insiders filed around the same period.

Relevance 4/10Novelty 8/10Timing: filed 2026-06-08 (covers sale dated 2026-06-04)

Background

The article is a SEC Form 4 insider transaction disclosure (director selling issuer shares).

Company-level read

Ticker impact

$CSTMNeutralMedium confidence
Context

Constellium director John Ormerod filed an open-market sale of 8,000 shares at $35.01 on 2026-06-04, leaving 24,873 shares.

Expected impact

Low near-term impact; any reaction is likely noise unless follow-on filings show sustained selling.

Evidence & confidence

The filing is a primary-source insider transaction, but it is not tied to new fundamentals, guidance, or corporate actions in the article.

Market effects

No sector read-across; this is a single-company insider transaction with no operational or regulatory linkage stated.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax- or diversification-driven; without a 10b5-1 plan and with a remaining large stake, the signal may be weaker than it looks.

Key entities

  • Constellium SE

    Subject of the Form 4 insider sale disclosure.

  • John Ormerod

    Director who sold 8,000 shares of CSTM.

Related articles

$CSTMHighAI 9/10

Constellium Raises Full-Year Outlook After Second-Quarter Earnings Top Expectations

Constellium SE (NYSE:CSTM) reported stronger-than-expected second-quarter results on Wednesday and increased its financial guidance for the full year, sending its shares more than 3% higher in pre-market trading. The aluminum products manufacturer posted adjusted earnings of $1.04 per share, comfortably ahead of analysts' consensus estimate of $0.71. Quarterly revenue rose to $2.75 billion, exceeding expectations of $2.37 billion and increasing 31% from $2.1 billion in the same period last year.

$CSTMMedAI 8/10

Constellium SE Q2 2026 Earnings Call Summary

Constellium SE reported record Q2 2026 Adjusted EBITDA of $310 million (excluding metal price lag) and raised full-year 2026 guidance to EUR 980 million to EUR 1.02 billion. It expects free cash flow above EUR 300 million and said recycling benefits may taper in H2 2026. The company also discussed aerospace demand, scrap spreads, and a potential European scrap export tax.

$CSTMMed

CONSTELLIUM SE (CSTM): Results of Operations and Financial Condition

CONSTELLIUM SE (CSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. cstm-20260729 false 0001563411 0001563411 2026-07-29 2026-07-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

$CSTMMedAI 8/10

Constellium (NYSE:CSTM) Shares Pass Above 200 Day Moving Average – Here’s Why

Constellium SE (NYSE:CSTM) shares moved above their 200-day moving average on Monday, trading up to $33.54 and last at $33.26 versus a 200-day average near $23.72. The stock also saw analyst changes: Zacks upgraded to strong-buy; Deutsche Bank reiterated buy with a $40 target; JPMorgan raised its $34 target. The company reported April 29 EPS of $1.42 and revenue of $2.46B, and approved a $300M buyback.